NK-cell and T-cell functions in patients with breast cancer: Effects of surgery and adjuvant chemo- and radiotherapy

British Journal of Cancer

Volumn 97, Issue 1, 2007, Pages 105-111

  Mozaffari, F ^a   Lindemalm, C ^a   Choudhury, A ^a   Granstam Bjorneklett H ^b   Helander, I ^a   Lekander, M ^c   Mikaelsson, E ^a   Nilsson, B ^a   Ojutkangas, M L ^d   Osterborg A ^a   Bergkvist, L ^d   Mellstedt, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Cytokines; Her 2; NK cytotoxicity; T cell signalling proteins

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL FUNCTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNE FUNCTION TEST; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; T-LYMPHOCYTES;

EID: 34347332446     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603840     Document Type: Article

References (27)

1. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259-267
2. Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL (2003) Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 33: 119-124
3. Berger M, Irschick E, Fritsch E, Frommhold H, Schonitzer D, Wiegele J, Kemmler G, Huber C (1990) Influence of local radiotherapy of breast cancer patients on the frequency of cytotoxic T lymphocyte precursor cells. Immunobiology 180: 261-271
4. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC (2005) TCR stimulation with modified anti-CD3mAb expands CD8+T cell population and induces CD8+CD25+Tregs. J Clin Invest 115: 2904-2913
5. Blake-Mortimer JS, Sephton SE, Carlson RW, Stites D, Spiegel D (2004) Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J 10: 195-199
6. Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6: 229-239
7. Caras I, Grigorescu A, Stavaru C, Radu DL, Mogos I, Szegli G, Salageanu A (2004) Evidence for immune defects in breast and lung cancer patients. Cancer Immunol Immunother 53: 1146-1152
8. Chan A, Martin M, Untch M (2006) Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 95: 788-793
9. Cheng F, Gabrilovich D, Sotomayor EM (2004) Immune tolerance in breast cancer. Breast Dis 20: 93-103
10. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446
11. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99: 3661-3667
12. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655
13. Henney CS, Kuribayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural killer cell activity. Nature 291: 335-338
14. Hudis CA (2003) Current status and future directions in breast cancer therapy. Clin Breast Cancer, 4 Suppl 2: S70-S75
15. Konjevic G, Spuzic I (1992) Evaluation of different effects of sera of breast cancer patients on the activity of natural killer cells. J Clin Lab Immunol 38: 83-93
16. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62: 5813-5817
17. Kurt RA, Urba WJ, Smith JW, Schoof DD (1998) Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int J Cancer 78: 16-20
18. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE (2003) Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer 105: 717-723
19. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761
20. Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F (2005) Thymic regulatory T cells. Autoimmun Rev 4: 579-586
21. Matar P, Rozados VR, Gervasoni SI, Scharovsky GO (2002) Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50: 588-596
22. Morse MA (2000) Technology evaluation: Theratope, Biomira Inc. Curr Opin Mol Ther 2: 453-458
23. Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H, Mellstedt H, Osterborg A (2004) Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 124: 315-324
24. Murta EF, de Andrade JM, Falcao RP, Bighetti S (2000) Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86: 403-407
25. Nicolini A, Ferrari P, Spinelli R, Carpi A, Sagripanti A, Ambrogi F (1996) Cell-mediated immunity in breast cancer patients. Biomed Pharmacother 50: 337-343
26. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897
27. Yi H, Rong Y, Yankai Z, Wentao L, Hongxia Z, Jie W, Rongyue C, Taiming L, Jingjing L (2006) Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Vaccine 24: 2575-2584